Pharmaceuticals News and Research

RSS

Actavis seeks FDA approval to market generic Opana ER

Watson Pharmaceuticals, Inc. today confirmed that Actavis South Atlantic LLC, which was acquired by Watson in October, has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Oxymorphone Hydrochloride Extended-release Tablets.

23 Jan 2013

$30 for a flu shot: An outrage or a bargain?

The Los Angeles Times looks at the economics of producing a successful flu vaccine each year. And Reuters explores what may be on the horizon to improve those immunizations.

23 Jan 2013

STA announces results from ABRAXANE plus gemcitabine phase III trial on pancreatic cancer

Australian biopharmaceutical company Specialised Therapeutics Australia announces that a phase III clinical trial of world leading breast cancer drug ABRAXANE (nanoparticle albumin-bound paclitaxel) in combination with current standard of care gemcitabine in patients with advanced pancreatic cancer has demonstrated substantially improved survival times, with double the number of patients surviving two years.

23 Jan 2013

Simcere enters share transfer agreement with Devont Asset Management

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced that the Company entered into a share transfer agreement with Devont Asset Management Limited on January 15th 2013 to sell an approximately 35% equity interest in Shanghai Celgen Bio-Pharmaceutical Co., Ltd. for a cash consideration of RMB 302 million.

22 Jan 2013

Psychiatrists exposed to COI policies during residency less likely to prescribe brand antidepressants

Psychiatrists who are exposed to conflict-of-interest (COI) policies during their residency are less likely to prescribe brand-name antidepressants after graduation than those who trained in residency programs without such policies, according to a new study by researchers from the Perelman School of Medicine at the University of Pennsylvania.

22 Jan 2013

FDA approves Ampio’s IND for Optina for treatment of diabetic macular edema

Ampio Pharmaceuticals, Inc. announced today that the FDA has accepted the Company's IND for Optina™ for the treatment of diabetic macular edema (DME). Ampio plans to commence enrollment in a clinical trial in the first quarter of 2013. The FDA granted Optina™ 505(b)(2) status in July, 2012. Drugs designated under this pathway can be approved on a single trial.

22 Jan 2013

Study reveals ugly cholesterol is the direct cause of ischaemic heart disease

The risk of ischaemic heart disease - a disease affecting some 150,000 Danes - is three times higher in persons with high levels of the so-called 'ugly' cholesterol. This is the finding of a new study of 73,000 Danes, which is shedding light on a long debate on this topic. The results have just been published in the Journal of the American College of Cardiology.

22 Jan 2013

New DNA chip could improve diagnosis and therapeutics of ADHD

Attention Deficit Hyperactivity Disorder (ADHD) is the most common childhood neuropsychiatric disorder. Yet there is currently no tool that will confirm the diagnosis of ADHD. In her thesis entitled "Development of a genotyping system to be applied in Attention Deficit Hyperactivity Disorder and its Pharmacogenetics".

22 Jan 2013

Study shows first empirical evidence of exposure to conflict-of-interest policies

19 Jan 2013

Stage IV cancer cells even more susceptible to grape seed extract than stage II

When the going gets tough, grape seed extract gets going: A University of Colorado Cancer Center study recently published in the journal Cancer Letters shows that the more advanced are colorectal cancer cells, the more GSE inhibits their growth and survival. On the other end of the disease spectrum, GSE leaves healthy cells alone entirely.

19 Jan 2013

NSU to host conference on neuro immune conditions

Nova Southeastern University (NSU) will be hosting a conference on Saturday, Jan. 26 about the upcoming opening of the NSU College of Osteopathic Medicine's Institute for Neuro Immune Medicine.

19 Jan 2013

New report highlights links between NTDs and socio-economic prosperity

A recently released report, entitled "Social and Economic Impact Review on Neglected Tropical Diseases," highlights links between neglected tropical diseases (NTDs) and socio-economic prosperity.

19 Jan 2013

Reports examine global NTD response one year after London declaration

Two reports released Wednesday provide an update on the global response against neglected tropical diseases (NTDs) a year after leaders of some of the world's largest pharmaceutical companies met in London and agreed to fight the diseases, Guardian health editor Sarah Boseley reports in her "Global Health Blog."

18 Jan 2013

Ceram to develop its Controlled Release Technology for the delivery of selected AstraZeneca compounds

AstraZeneca, a global pharmaceutical company, has signed an agreement with Ceram Research Ltd, the international materials development company, for Ceram to develop its Inorganic-based Controlled Release Technology in a feasibility study for the delivery of selected AstraZeneca compounds.

18 Jan 2013

Rochester scientists propose new reason why acute myeloid leukemia is so difficult to cure

University of Rochester Medical Center scientists have proposed a new reason why acute myeloid leukemia, one of the most aggressive cancers, is so difficult to cure: a subset of cells that drive the disease appear to have a much slower metabolism than most other tumors cells.

18 Jan 2013

Children's Oakland recruits patients for deferiprone clinical trial to treat PKAN

A groundbreaking, international clinical trial of an iron chelation drug, deferiprone, to treat the rare and devastating neurodegenerative disease, pantothenate kinase-associated neurodegeneration (PKAN), began last month at the trial's only North American site, Children's Hospital & Research Center Oakland.

17 Jan 2013

SyNAPSe® Trial by BHR Pharma deemed to have no safety issues according to DSMB

BHR Pharma, LLC announced today that the SyNAPSe® Trial's independent Data and Safety Monitoring Board (DSMB) evaluated safety data from 803 randomized patients and determined that no issues exist; therefore, the trial may continue towards its intended completion.

17 Jan 2013

MPL vaccine can stimulate brain's natural defense mechanisms in people with AD

A team of researchers from Universit- Laval, CHU de Qu-bec, and pharmaceutical firm GlaxoSmithKline (GSK) has discovered a way to stimulate the brain's natural defense mechanisms in people with Alzheimer's disease.

17 Jan 2013

UCLA, NanoSmart partner to develop novel cancer drug delivery platform

NanoSmart Pharmaceuticals, a private biotechnology company, has entered into a research collaboration agreement with University of California Los Angeles (UCLA) to continue the development of NanoSmart's novel drug delivery platform for the treatment of cancer and other life-threatening diseases.

17 Jan 2013

Tzamal Medical, Duchesnay partner to distribute and sell Diclectin for management of NVP

Duchesnay Inc. and Tzamal Medical Group Ltd today announced that they have signed an agreement whereby Tzamal Medical Group has been granted exclusive rights to distribute and sell throughout the Israeli market the prescription medicine Diclectin (doxylamine 10 mg/pyridoxine 10 mg delayed-release tablet) indicated for the management of nausea and vomiting of pregnancy (NVP).

17 Jan 2013

Pharmaceuticals News and Research

Actavis seeks FDA approval to market generic Opana ER

$30 for a flu shot: An outrage or a bargain?

STA announces results from ABRAXANE plus gemcitabine phase III trial on pancreatic cancer

Simcere enters share transfer agreement with Devont Asset Management

Psychiatrists exposed to COI policies during residency less likely to prescribe brand antidepressants

FDA approves Ampio’s IND for Optina for treatment of diabetic macular edema

Study reveals ugly cholesterol is the direct cause of ischaemic heart disease

New DNA chip could improve diagnosis and therapeutics of ADHD

Study shows first empirical evidence of exposure to conflict-of-interest policies

Stage IV cancer cells even more susceptible to grape seed extract than stage II

NSU to host conference on neuro immune conditions

New report highlights links between NTDs and socio-economic prosperity

Reports examine global NTD response one year after London declaration

Ceram to develop its Controlled Release Technology for the delivery of selected AstraZeneca compounds

Rochester scientists propose new reason why acute myeloid leukemia is so difficult to cure

Children's Oakland recruits patients for deferiprone clinical trial to treat PKAN

SyNAPSe® Trial by BHR Pharma deemed to have no safety issues according to DSMB

MPL vaccine can stimulate brain's natural defense mechanisms in people with AD

UCLA, NanoSmart partner to develop novel cancer drug delivery platform

Tzamal Medical, Duchesnay partner to distribute and sell Diclectin for management of NVP

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence